advertising
-
1
Niknejad H, Peirovi H, Jorjani M, et al: Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater 15: 88, 2008.
-
2
Koob TJ, Rennert R, Zabek N, et al: Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. Int Wound J 10: 493, 2013.
-
3
Zelen CM, Serena TE, Denozière G, et al: A prospective randomized comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. Int Wound J 10: 502, 2013.
-
4
Zelen CM, Serena TE, Snyder RJ: A prospective, randomised comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers. Int Wound J 11: 122, 2014.
-
5
Zelen CM, Gould L, Serena TE, et al: A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J 12: 724, 2015.
-
6
Zelen CM, Serena TE, Gould L, et al: Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J 13: 272, 2016.
-
7
Serena TE, Carter MJ, Le LT, et al: A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. Wound Repair Regen 22: 688, 2014.
-
8
American Diabetes Association: Statistics about diabetes. Available at: http://www.diabetes.org/diabetes-basics/statistics/?referrer=https://www.google.com/#sthash.jBP0GUdN.dpuf. Accessed September 20, 2016.
-
9
Strauss MB, Moon H, La S, et al: The incidence of confounding factors in patients with diabetes mellitus hospitalized for diabetic foot ulcers. Wounds 28: 287, 2016.
-
10
Mrugala A, Sui A, Plummer M, et al: Amniotic membrane is a potential regenerative option for chronic non-healing wounds: a report of five cases receiving dehydrated human amnion/chorion membrane allograft. Int Wound J 13: 485, 2016.
-
11
Tenenhaus M, Greenberg M, Potenza B: Dehydrated human amnion/chorion membrane for the treatment of severe skin and tissue loss in a preterm infant: a case report. J Wound Care 23: 490, 2014.
-
12
Sheikh ES, Sheikh ES, Fetterolf DE: Use of dehydrated human amniotic membrane allografts to promote healing in patients with refractory non healing wounds. Int Wound J 11: 711, 2014.
-
13
Snyder RJ, Ead J, Glick B, et al: Dehydrated human amnion/chorion membrane as adjunctive therapy in the multidisciplinary treatment of pyoderma gangrenosum: a case report. Ostomy Wound Manage 61: 40, 2015.
-
14
Wisco OJ: Case series: the use of a dehydrated human amnion/chorion membrane allograft to enhance healing in the repair of lower eyelid defects after Mohs micrographic surgery. JAAD Case Rep 2: 294, 2016.
Use of Dehydrated Human Amnion/Chorion Membrane Allografts in More Than 100 Patients with Six Major Types of Refractory Nonhealing Wounds
Search for other papers by Matthew Garoufalis in
Current site
Google Scholar
PubMed
Search for other papers by Darshan Nagesh in
Current site
Google Scholar
PubMed
Search for other papers by Patrick J. Sanchez in
Current site
Google Scholar
PubMed
Search for other papers by Robin Lenz in
Current site
Google Scholar
PubMed
Search for other papers by Sarah J. Park in
Current site
Google Scholar
PubMed
Search for other papers by Jake G. Ruff in
Current site
Google Scholar
PubMed
Search for other papers by Anna Tien in
Current site
Google Scholar
PubMed
Search for other papers by Justin Goldsmith in
Current site
Google Scholar
PubMed
Search for other papers by Andrea Seat in
Current site
Google Scholar
PubMed
Background:
Biochemical properties of the amniotic membrane help modulate inflammation and enhance soft-tissue healing. In controlled trials, the efficacy of dehydrated human amnion/chorion membrane (dHACM) allografts has been established. Our purpose is to describe our experience with using dHACM to treat nonhealing wounds of various etiologies.
Methods:
We conducted a retrospective review of deidentified data from 117 consecutive patients treated in an outpatient clinic with dHACM allografts with wounds of various etiologies over 2 years. The decision to use advanced wound-care treatments is based on rate of healing observed after initiation of standard wound care and patient risk factors. Eligibility for treatments such as amniotic membrane allografts includes wounds without 50% reduction after 4 weeks, or earlier in patients deemed to be at high risk for nonhealing or with a history of chronic wounds. In micronized or sheet formulation, dHACM is applied to the wound weekly after sharp/mechanical debridement as necessary, and wound-care practices appropriate for wound type and location are continued.
Results:
Thirty-four percent of allograft recipients had diabetic foot ulcers, 25% had venous leg ulcers, 20% had surgical wounds, 14% had pressure ulcers, 6% had ischemic wounds, and 2% had traumatic wounds. Complete healing occurred in 91.1% of treated patients, with a mean ± SD number of weekly applications per healed wound of 5.1 ± 4.2.
Conclusions:
In addition to wounds of diabetic origin, dHACM can significantly expedite healing in refractory wounds of varying etiologies.
advertising
advertising
